An analysis revealed that as a third- or fourth-line treatment for advanced renal cell carcinoma, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in TWiST.
Results of an analysis of tivozanib (Fotivda) versus sorafenib (Nexavar) in patients with advanced renal cell carcinoma (RCC) included in the phase 3 TIVO-3 study (NCT02627963) suggest Q-TWiST may be considered an alternative patient-centered measure of benefit in these settings.
The analysis, presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancers Symposium, revealed that as a third- or fourth-line treatment for RCC, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in TWiST.
In an interview with CancerNetwork®, Michael Szarek, PhD, of the SUNY Downstate Medical Center, spoke about the next steps for tivozanib in this patient population.
First, we’re looking to publish more details on this particular analysis; we’re looking to publish the manuscript about it. The drug itself is approved in Europe, but it’s not yet approved in the United States; however, the [new drug application] is under review currently. This drug has been studied in front-line renal cell cancer and in later-line [settings]. The sponsor, who is Aveo, is hoping that these TIVO-3 trial results will support its approval. From my understanding, it’s currently under review. The results of that review are pending.
Szarek M, Needle MN, Rini BI, et al. Q-TWiST analysis of tivozanib (T) versus sorafenib (S) in patients with advanced renal cell carcinoma (RCC) in the TIVO-3 study. J Clin Oncol. 2021;39(suppl 6):298. doi: 10.1200/JCO.2021.39.6_suppl.298